Apogee Therapeutics Inc. Common Stock (APGE) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 35.33
(+81.10%)
Based on the Apogee Therapeutics Inc. Common Stock stock forecast from 6 analysts, the average analyst target price for Apogee Therapeutics Inc. Common Stock is USD 35.33 over the next 12 months. Apogee Therapeutics Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apogee Therapeutics Inc. Common Stock is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Apogee Therapeutics Inc. Common Stock’s stock price was USD 19.51. Apogee Therapeutics Inc. Common Stock’s stock price has changed by +13.23% over the past week, +17.04% over the past month and 0% over the last year.
No recent analyst target price found for Apogee Therapeutics Inc. Common Stock
No recent average analyst rating found for Apogee Therapeutics Inc. Common Stock
Company Overview Apogee Therapeutics Inc. Common Stock
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Address: Read Less
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily dev...Read More
N/A
N/A
0
N/A
USD
USA
Adjusted Closing Price for Apogee Therapeutics Inc. Common Stock (APGE)
Loading...
Unadjusted Closing Price for Apogee Therapeutics Inc. Common Stock (APGE)
Loading...
Share Trading Volume for Apogee Therapeutics Inc. Common Stock Shares
Loading...
Compare Performance of Apogee Therapeutics Inc. Common Stock Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for APGE
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Apogee Therapeutics Inc. Common Stock (Sector: Biotechnology )
Frequently Asked Questions About Apogee Therapeutics Inc. Common Stock (APGE) Stock
Based on ratings from 6 analysts Apogee Therapeutics Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on APGE's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for APGE is USD 35.33 over the next 12 months. The maximum analyst target price is USD 40 while the minimum anlayst target price is USD 29.
Unfortunately we do not have enough data on APGE's stock to indicate if its overvalued.
The last closing price of APGE's stock was USD 19.51.
Unfortunately we do not currently have any market capitalization data for APGE's stock.
Based on targets from 6 analysts, the average taret price for APGE is projected at USD 35.33 over the next 12 months.
This means that APGE's stock price may go up by +81.10% over the next 12 months.
We can't find any ETFs which contains Apogee Therapeutics Inc. Common Stock's stock.
As per our most recent records Apogee Therapeutics Inc. Common Stock has 0 Employees.
Sorry we do not have any infomation available on Apogee Therapeutics Inc. Common Stock's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APGE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
